Efficacy

Strattera is a non-stimulant prescription medicine, proven to effectively treat symptoms of ADHD in children aged 6 and older. However, it′s important to keep in mind that every child is different, and Strattera does not work for everyone, even when it is taken exactly as directed.

If Strattera works for your child, it may help to:

  • Improve their attentiveness
  • Decrease their hyperactivity
  • Reduce their impulsivity

Strattera® offers significant reductions of ADHD core symptoms - Inattention, Hyperactivity/Impulsivity

Strattera

Data pooled from 6 studies displaying the efficacy of Strattera in treating ADHD core symptoms. In study III, 1.2 mg/kg/day is a fixed dose, while in all other studies, this dose represents a titrated dose.

Strattera® provides continuous symptoms control, from one morning into the next morning10

Strattera

Benefits in Morning Behaviors4

  • Getting out of bed
  • Getting ready for school
  • Less arguing/struggling
Study summary
Citation Block SL. Clin Pediatr (Phila) 2009; 48(7): 723-33.
Study Design Three-arm, randomised, double-blind trial, once-daily morning-dosed atomoxetine, evening-dosed atomoxetine, and placebo compared for treating pediatric ADHD.
Duration 6 weeks.
Dose Mean final doses of 1.25 and 1.26 mg/kg b.w./d atomoxetine for AM and PM atomoxetine, respectively.
N Morning atomoxetine/evening placebo (n=102), morning placebo/evening atomoxetine (n=93), morning placebo/evening placebo (n=93).
Results Morning-dosed and evening-dosed atomoxetine significantly decreased core ADHD symptoms relative to placebo and produced symptom improvements that were measured up to 24 hours later. Morning dosing was superior to evening dosing on some efficacy measures.

Strattera

Benefits in Evening Behaviors4

  • Completing homework/tasks
  • Sitting through dinner
  • Laying quietly
  • Attentive and focus
  • Ease of transitioning
  • Settling at bedtime
  • Falling asleep
Study summary
Citation Kelsey D, et al. Poster presented at the 13th international congress of the European society for child and adolescent psychiatry (ESCP); Florence, Italy, 2007.
Study Design Multicenter, randomised, placebo-controlled, double-blind trials to assess the duration of atomoxetine on core ADHD symptoms and behaviors.
Duration Trial 1 – 8 weeks; Trial 2 – 6 weeks.
Dose Trial 1 - maximum dose of 1.8 mg/kg b.w./d; Trial 2 - maximum dose of 1.4 mg/kg b.w./d.
N Trial 1 - 197 patients; Trial 2 - 288 patients.
Results In Trial 1, atomoxetine was more effective than PLA on the ADHD Rating Scale (ADHD RS), Conners Global Index Parent-Evening (CGIP-E) Total score and the Daily Parent Rating of Evening and Morning Behavior-Revised (DPREMB-R) Evening subscore. The DPREMB-R Morning subscore showed symptom reduction into the next AM. In Trial 2, morning and evening atomoxetine were superior to PLA on the ADHD RS Total score. Morning atomoxetine was superior to evening ATX on the ADHD RS Total score and Hyperactive/Impulsive subscore. Significant efficacy up to 18 hours later was shown for morning atomoxetine on the DPREMB-R Evening subscore, CGIP-E Total score, and CGIP-E Restless-Impulsive subscore and for evening atomoxetine on the CGIP-M Total score and CGIP-M Restless-Impulsive subscore. Significant efficacy up to 24 hours later was shown for morning atomoxetine on the CGIP-M Total score, and for evening atomoxetine on the CGIP-E Total score, CGIP-E Restless-Impulsive subscore, and DPREMB-R Evening subscore.

Strattera® provides long term stability over time in treating ADHD

ADHD-RS-IV-Parent:Inv scores over 2 years

Date pooled from 13 Strattera® studies of subject aged 12 to 18 with ADHD as defined by the DSM-IV criteria. Of 601 subjects in this meta analysis, 219 completed at least 2 years of Strattera® treatment. The studies used similar dose ranges, with a target dose of 1.2mg/kg/day to a maximum dose of 1.8mg/kg/day, administered either as a once-daily dose or as a divided twice-daily dose. Primary efficacy was measured using the ADHD-RS-IV .

Study summary
Citation Wilens TE, et al. J Pediatr. 2006; 149(1): 112-9.
Study Design 6 double-blind, 7 open-label studies to determine the efficacy and safety of atomoxetine in adolescent subjects treated for ADHD.
Duration Up to 2 years.
Dose Mean dose 1.41 mg/kg b.w./d atomoxetine.
N 601 patients.
Results Of the 601 atomoxetine-treated subjects, 537 (89.4%) completed 3 months of acute treatment. A total of 259 subjects (48.4%) were continuing atomoxetine treatment; 219 of these subjects had completed at least 2 years of treatment. Mean ADHD Scale IV, parent version, investigator-administered and -scored total scores showed significant improvement (p<0.001) over the first 3 months. Symptoms remained improved up to 24 months without dosage escalation. During the 2-year treatment period, 99 (16.5%) subjects discontinued treatment due to lack of effectiveness, and 31 (5.2%) subjects discontinued treatment due to adverse events.

Strattera® improves emotional well-being & self-esteem of ADHD Patients

CHQ Psychosocial Components

In the study, a total of 297 children and adolescents who were 8 to 18 years of age and had ADHD as defined by DSM-IV, were randomized to placebo or Strattera® dosed on a weight-adjusted basis at 0.5mg/kg/day, 1.2mg/kg/day for an 8-week period. Improvements in social and family functioning were superior among Strattera® treated patients compared with those in the placebo group.

Study summary
Citation Michelson D, et al. Pediatrics 2001; 108(5): E83.
Study Design Randomised, placebo-controlled, dose-response study to assess the efficacy of 3 doses of atomoxetine compared with placebo in children and adolescents with ADHD.
Duration 8 weeks.
Dose 0.5 mg/kg b.w./d, 1.2 mg/kg/d, or 1.8 mg/kg b.w./d atomoxetine.
N 297 patients.
Results At baseline, symptom severity was rated as moderate to severe for most children. At endpoint, atomoxetine 1.2 mg/kg b.w./d and 1.8 mg/kg b.w./d were consistently associated with superior outcomes in ADHD symptoms compared with placebo and were not different from each other. The dose of 0.5 mg/kg b.w./d was associated with intermediate efficacy between placebo and the 2 higher doses, suggesting a graded dose-response. Social and family functioning also were improved in the atomoxetine groups compared with placebo with statistically significant improvements in measures of children's ability to meet psychosocial role expectations and parental impact.

HKGSTR2015-09-29T13_36_09




Last Update: 26 Oct 2015

Top
TGlsbHkwMS0wNjIwMTY=